Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)

HS 2014-9994
Alzheimer’s, Dementia, Memory disorders, Memory loss
Aimee L. Pierce, MD

UCI MIND at Gottschalk Medical Plaza, UC Irvine Health Institute for Clinical & Translational Science at Hewitt Hall on the Irvine campus, the UC Irvine Brain Imaging Center in Irvine Hall.

To evaluate whether immunization treatment with solanezumab versus a placebo will slow cognitive decline in individuals showing the presence of an elevated protein called amyloid on a brain scan.

Male and female participants between 65 and 85 years of age who have evidence of elevated brain amyloid pathology on a brain scan.

The screening phase is up to 90 days; the treatment phase involves 48 visits over the course of up to 168 weeks, or about 3 years.


You may or may not receive any benefit from being in this study. If you are in the group that receives the study drug solanezumab, and it proves to treat your condition better than placebo, you may benefit from participating in the study. But this cannot be guaranteed.

The information collected from this study may increase knowledge regarding the treatment of Alzheimer’s disease and help people in the future.


Participants are eligible to receive the following compensation in cash during the course of this study:

  • $100 for each completed MRI scan; there are 4 MRI scans ($400 max)
  • $100 for each completed PET scan; there are 2 PET scans ($200 max)
  • $100 for each completed lumbar puncture; there are two optional lumbar punctures ($200 max)
  • $40 for each infusion visit requiring infusion; there are 42 infusion visits in this study ($1680 max)

The grand total compensation for this study is a maximum of $2,480 in cash.

Participants will not be reimbursed for travel-related expenses.

Solanezumab
Drug therapy
Beatriz Yanez, RN, clinical research nurse and coordinator
949-824-3250